Company: TELO
Filing Date: 2025-02-14
Form Type: S-3
Source: 0001493152-25-006943
Chunk: 42

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-3
Chunk 42
---
-11 |

| ● | the                                                                                                                                        
 timing or likelihood of the accomplishment of various scientific, clinical, regulatory, and other product development objectives;          |
| ● | the                                                                                                                                        
 pricing and reimbursement of our product candidates, if approved by the FDA;                                                               |
| ● | the                                                                                                                                        
 rate and degree of market acceptance of our product candidates, if approved by the FDA;                                                    |
| ● | the                                                                                                                                        
 implementation of our business model and strategic plans for our business, product candidates, and technology;                             |
| ● | the                                                                                                                                        
 scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; |
| ● | developments                                                                                                                               
 relating to our competitors and our industry;                                                                                              |
| ● | the                                                                                                                                        
 development of major public health concerns, including pandemics arising globally, and the future impact of such events on our business    
 operations and funding requirements; and                                                                                                   |
| ● | other                                                                                                                                      
 risks and factors listed under “Risk Factors” and elsewhere in or incorporated by reference in this prospectus.                            |

You should review carefully the section entitled “Risk Factors” beginning on page 5 of this prospectus for a discussion of these and other risks that relate to our business and investing in our securities. The forward-looking statements contained or incorporated by reference in this prospectus are expressly qualified in their entirety by this cautionary statement. Except as required by applicable law, we do not undertake any obligation to publicly update any forward-looking statement contained in this prospectus, the accompanying base prospectus or the documents incorporated by reference herein to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

| Alt-12 |

<div align='center'>USE OF PROCEEDS</div>

We may issue and sell shares of common stock having aggregate sales proceeds of up to $100,000,000 from time to time, before deducting sales agent commissions and estimated offering expenses payable by us. The amount of proceeds from this offering, if any, will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with Rodman & Renshaw.

We will retain broad discretion over the use of the net proceeds from